FOR IMMEDIATE RELEASE
For the third time in four years, prostate cancer research is increased by $10M
Washington, D.C. – Bipartisan congressional support has increased funding for the Prostate Cancer Research Program (PCRP) to a historic level of $110M. This approved increase of $10M will begin in FY20, and will help seed more research projects to bring innovative breakthroughs from the science bench to the patients’ bedside.
Prostate cancer — which kills a man every 17 minutes — has only about a 30 percent survival rate once it reaches advanced stages, making new treatment options for those with advanced disease critical to survival.
“Patients like Steve Bleser with advanced prostate cancer have limited treatment options,” said ZERO CEO, Jamie Bearse. “With this additional research funding from Congress, Steve and patients across the nation can now have hope that new breakthroughs will be in the pipeline. Amazing milestones like this only happen because of our dedicated and passionate champions from around the country who are tireless in sharing our mission to end prostate cancer.”
Previous PCRP funding has led to the commercial development of four advanced prostate cancer treatments and one new diagnostic test. The four treatments are XGEVAⓇ, ZYTIGAⓇ, XTANDIⓇ, and ERLEADAⓇ. The advanced diagnostic test is the Oncotype DX AR-V7 Test.
Steve Bleser, an advanced prostate cancer patient in North Carolina, helped bring the increased funding by sharing his story with his elected officials in Congress. “I’ve done chemo, radiation, and many other treatments. My doctors say there are no more options for me,” said Bleser. “This is unacceptable. I won’t give up this fight — funding research is critical to help men like me live longer and have more time.
Bleser is just one of the hundreds of fierce advocates and ZERO Champions from around the country who have attended the ZERO Prostate Cancer Summit, an annual advocacy event on Capitol Hill that brings awareness to the critical need for more prostate cancer research funding.
This latest round of PCRP funding was championed by Congressional leaders with bipartisan support. Reps. Sanford Bishop (D-GA), Rep. Peter King (R-NY), Sen. Mike Crapo (R-ID), and Sen. Robert Menendez (D-NJ) spearheaded the effort to secure PCRP funding, collecting signatures from more than 170 House and Senate members on letters to the appropriations committee.
About ZERO — The End of Prostate Cancer
ZERO — The End of Prostate Cancer is the leading national nonprofit with the mission to end prostate cancer and help all who are impacted. ZERO advances research, provides support, and creates solutions to achieve health equity to meet the most critical needs of our community. From early detection to survivorship, ZERO is the premier resource for prostate cancer patients and their families to access comprehensive support, make meaningful connections, and take action to save lives. Our dedicated national and chapter staff is joined with a growing team of passionate volunteer champions to increase advocacy, awareness, and community engagement to ZERO out prostate cancer. ZERO is recognized with four out of four stars by Charity Navigator and accredited by the Better Business Bureau. ZERO spends more on programs than any other prostate cancer charity, dedicating 85 cents of every dollar to support, education, and research.